Dealing with the spiralling price of medicines: issues and solutions

Internal Medicine Journal

Volumn 48, Issue 1, 2018, Pages 16-24

  Ma, Chun K K ^a,b   Danta, Mark ^a,b   Day, Richard ^a,b   Ma, David D F ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

cost effectiveness; drug cost; escalating medicine price; financial toxicity; medicine affordability; medicine toxicity

Indexed keywords

ANTIVIRUS AGENT; ECULIZUMAB; ENZALUTAMIDE; ERLOTINIB; ETANERCEPT; IMATINIB; IPILIMUMAB; PYRIMETHAMINE; RADOTINIB; THALIDOMIDE; TOCILIZUMAB;

AUSTRALIA; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; FUNDING; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH PRACTITIONER; HEPATITIS C; HUMAN; LIFE EXPECTANCY; MEDICAL INFORMATICS; MULTIPLE MYELOMA; NAUSEA; OVERALL SURVIVAL; PANCREAS CANCER; PARASITOSIS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATENT; PATIENT CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; RHEUMATOID ARTHRITIS; SURVIVAL TIME; ECONOMICS; EDUCATION; EPIDEMIOLOGY; HEALTH CARE DELIVERY; TRENDS;

AUSTRALIA; DELIVERY OF HEALTH CARE; DRUG COSTS; DRUG INDUSTRY; HUMANS;

EID: 85040056409     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.13652     Document Type: Review

References (61)

1. Zafar SY, Abernethy AP. Financial toxicity, part I: a new name for a growing problem. Oncology (Williston Park) 2013; 27: 80–1 149.
2. Karikios DJ, Schofield D, Salkeld G, Mann KP, Trotman J, Stockler MR. Rising cost of anticancer drugs in Australia. Intern Med J 2014; 44: 458–63.
3. health.gov.au [homepage on the internet]. Turnbull government invests over $1 billion to cure HEP C. [updated 2015 Dec 22; cited 2016 Apr 18]. Available from URL: https://www.health.gov.au/internet/ministers/publishing.nsf/Content/health-mediarel-yr2015-ley154.htm
4. Etanercept. 2017 [cited 2017 Feb 28]. Available from URL: http://www.mims.com.au
5. Tocilizumab. 2017 [cited 2017 Feb 28]. Available from URL: http://www.mims.com.au
6. Alexionpharma.com.au. Rare and ultra-rare diseases [cited 2016 Dec 14]. Available from URL: https://alexionpharma.com.au/Patients/Ultra-Rare-Diseases
7. Constantino T. IMS health study: global market for cancer treatments grows to $107 billion in 2015, fueled by record level of innovation. New Jersey: QuintilesIMS. [updated 2016 Jun 2; cited 2017 Feb 9]. Available from URL: http://www.imshealth.com/en/about-us/news/ims-health-study-global-market-for-cancer-treatments-grows-to-107-billion-in-2015-fueled-by-record-level-of-innovation
8. Phelan M, Cook C. A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients. BMC Infect Dis 2014; 14(Suppl 6): S5.
9. Bach PB. Walking the tightrope between treatment efficacy and price. J Clin Oncol 2016; 34: 889–90.
10. Salas-Vega S, Iliopoulos O, Mossialos E. Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines. JAMA Oncol 2017; 3: 382–90.
11. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect 2015; 29: 139–62.
12. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium--the just price. J Clin Oncol 2013; 31: 3600–4.
13. Light DW, Kantarjian H. Market spiral pricing of cancer drugs. Cancer 2013; 119: 3900–2.
14. Grössmann N, Wild C. Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval? ESMO Open 2017; 1: e000125.
15. Hill A, Redd C, Gotham D, Erbacher I, Meldrum J, Harada R. Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis. BMJ Open 2017; 7: e011965.
16. Avorn J. The $2.6 billion pill--methodologic and policy considerations. N Engl J Med 2015; 372: 1877–9.
17. Saltz LB. The value of considering cost, and the cost of not considering value. J Clin Oncol 2016; 34: 659–60.
18. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013; 121: 4439–42.
19. Gagnon MA. New drug pricing: does it make any sense? Prescrire Int 2015; 24: 192–5.
20. Andrieux-Meyer I, Cohn J, de Araujo ES, Hamid SS. Disparity in market prices for hepatitis C virus direct-acting drugs. Lancet Glob Health 2015; 3: e676–7.
21. Kantarjian H, Zwelling L. Cancer drug prices and the free-market forces. Cancer 2013; 119: 3903–5.
22. Pollack A. Once a neglected treatment, now an expensive specialty drug. The New York Times (New York edition), September 2015.
23. Pollack A. Last shot at EpiPen profits ends in a Mylan monopoly. The New York Times (New York edition), August 2016.
24. Anand G. How drug's rebirth as treatment for cancer fueled price rises. Wall St J 2004; A1, A18.
25. Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol 2014; 15: e112–8.
26. Kushnick HL. Pricing cancer drugs: when does pricing become profiteering? AMA J Ethics 2015; 17: 750–3.
27. Klusty T. A legal test for the pharmaceutical company practice of ‘product hopping’. AMA J Ethics 2015; 17: 760–2.
28. Vernaz N, Haller G, Girardin F, Huttner B, Combescure C, Dayer P et al. Patented drug extension strategies on healthcare spending: a cost-evaluation analysis. PLoS Med 2013; 10: e1001460.
29. Mailankody S, Prasad V. Comparative effectiveness questions in oncology. N Engl J Med 2014; 370: 1478–81.
30. Group ES, Carey D, Puls R, Amin J, Losso M, Phanupak P et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis 2015; 15: 793–802.
31. Ghinea N, Lipworth W. Affordable access to innovative cancer medicines – don't forget the prices. Med J Aust 2016; 204: 214–5.
32. Faunce T. How the US Trade Deal Undermined Australia’s PBS. Canberra: Australian National University; 2014.
33. Aubusson K. Call to declare big pharma cash injection. The Sydney Morning Herald, January 2017.
34. Rose SL, Highland J, Karafa MT, Joffe S. Patient advocacy organizations, industry funding, and conflicts of interest. JAMA Intern Med 2017; 177: 344–50.
35. Kaplan RM, Milstein A. Financial strain and cancer outcomes. J Clin Oncol 2016; 34: 1711–2.
36. Roe OD. The high cost of new cancer therapies: a challenge of inequality for all countries. JAMA Oncol 2017; 3: 1169–70.
37. Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 2013; 18: 381–90.
38. Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 2006; 166: 332–7.
39. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 2014; 32: 306–11.
40. Simoens S, Sinnaeve PR. Patient co-payment and adherence to statins: a review and case studies. Cardiovasc Drugs Ther 2014; 28: 99–109.
41. Meeker CR, Geynisman DM, Egleston BL, Hall MJ, Mechanic KY, Bilusic M et al. Relationships among financial distress, emotional distress, and overall distress in insured patients with cancer. J Oncol Pract 2016; 12: e755–64.
42. Ramsey SD, Bansal A, Fedorenko CR, Blough DK, Overstreet KA, Shankaran V et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 2016; 34: 980–6.
43. Laba TL, Usherwood T, Leeder S, Yusuf F, Gillespie J, Perkovic V et al. Co-payments for health care: what is their real cost? Aust Health Rev 2015; 39: 33–6.
44. Vitry AI, Shin NH, Vitre P. Assessment of the therapeutic value of new medicines marketed in Australia. J Pharm Policy Pract 2013; 6: 2.
45. Godman B, Malmstrom RE, Diogene E, Gray A, Jayathissa S, Timoney A et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol 2015; 8: 77–94.
46. FixHepC.com. Cure hepatitis C with sofosbuvir ledipasvir daclatasvir; 2015 [updated 2016 Nov 29; cited 2016 Apr 18]. Available from URL: http://fixhepc.com
47. Ghinea N, Lipworth W, Day R, Hill A, Dore GJ, Danta M. Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries. Lancet 2016; 389: 1268–72.
48. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW et al. Support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc 2015; 90: 996–1000.
49. Berlinger N. Why clinical oncologists should talk about the price of cancer drugs. Virtual Mentor 2013; 15: 677–80.
50. Bach PB. Indication-specific pricing for cancer drugs. JAMA 2014; 312: 1629–30.
51. Bjorkhem-Bergman L, Andersen-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol 2013; 69(Suppl 1): 73–8.
52. Gustafsson LL, Wettermark B, Godman B, Andersen-Karlsson E, Bergman U, Hasselstrom J et al. The 'wise list': a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 2011; 108: 224–33.
53. Parkinson B, Sermet C, Clement F, Crausaz S, Godman B, Garner S et al. Disinvestment and value-based purchasing strategies for pharmaceuticals: an international review. Pharmacoeconomics 2015; 33: 905–24.
54. Chabner BA, Roberts TG. Setting fair prices for life-saving drugs. Virtual Mentor 2007; 9: 38–43.
55. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091–6.
56. Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol 2015; 1: 539–40.
57. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009; 101: 1044–8.
58. Monitoring Hepatitis C Treatment Uptake in Australia (Issue 6). Sydney: The Kirby Institute; 2017.
59. Duckett SJ, Breadon P, Ginnivan L, Venkataraman P. Australia's Bad Drug Deal: High Pharmaceutical Prices. Melbourne: Gratton Institute; 2013.
60. Monaghan A. Pfizer fined record £84.2m over NHS overcharging. The Guardian, December 2016.
61. Moynihan R, Bero L. Toward a healthier patient voice: more independence, less industry funding. JAMA Intern Med 2017; 177: 350–1.